文献速递核素与放射性配体治疗肿瘤 PET/CT

一项评估治疗性放射性药物131I-MIP-1095治疗转移性去势抵抗性前列腺癌安全性与耐受性的1期开放标签剂量递增研究

A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Clin Nucl Med · 2023-01-01

本研究为131I-MIP-1095在转移性去势抵抗性前列腺癌(mCRPC)患者中的首次1期剂量递增研究,入组9例对第二代抗雄激素及紫杉烷化疗难治的男性。基于剂量学结果,9例中5例接受治疗(队列1为50 mCi的3例,队列2为75 mCi的2例);未发生死亡、严重不良事件或因治疗中出现的不良事件停药,1例(33.3%)PSA最大下降≥50%。

要点

  • 9例mCRPC患者中5例接受治疗:队列1为50 mCi的3例,队列2为75 mCi的2例。
  • 腮腺/唾液腺(3.5 Gy/Bq)、肝(2.2 Gy/Bq)、肾(1.3 Gy/Bq)、脾(0.7 Gy/Bq)的131I-MIP-1095暴露最高。
  • 无死亡、严重不良事件或因治疗中出现的不良事件停药;1例(33.3%)PSA最大下降≥50%。

核心结论

  • 131I-MIP-1095显示出良好的剂量学、生物分布和安全性,以及适度的PSA反应,支持进一步研究其用于mCRPC男性的治疗。

研究设计与样本

  • 首次1期、开放标签、剂量递增研究,采用3+3设计方法,在mCRPC患者中评估131I-MIP-1095。
  • 入组对第二代抗雄激素和紫杉烷化疗难治的mCRPC男性,共9例被纳入研究。
  • 进行了剂量学/生物分布评估;安全性和耐受性在接受治疗者中确定,最大耐受活度按剂量递增方式考察。
  • 评估的疾病结局包括前列腺特异性抗原(PSA)变化、肿瘤反应、生存和循环肿瘤细胞浓度。

主要发现

  • 基于剂量学结果,9例中5例接受治疗:队列1(50 mCi)3例,队列2(75 mCi)2例。
  • 因美国食品药品监督管理局对131I-MIP-1095生产问题的强制要求,入组在队列2活度水平停止。
  • 腮腺/唾液腺(3.5 Gy/Bq)、肝(2.2 Gy/Bq)、肾(1.3 Gy/Bq)和脾(0.7 Gy/Bq)显示131I-MIP-1095暴露程度最高。
  • 无死亡、严重不良事件或因治疗中出现的不良事件停药;最常见为1-2级血小板减少、贫血、白细胞减少和口干。
  • 1例受试者(33.3%)PSA反应达到最大下降50%或以上。

临床怎么用

  • 原文结论为131I-MIP-1095显示出良好的剂量学、生物分布和安全性以及适度的PSA反应,支持进一步研究其用于mCRPC男性的治疗。

局限性

  • 入组在队列2活度水平停止,系回应美国食品药品监督管理局对131I-MIP-1095生产问题的强制要求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 131I-MIP-1095 is a targeted radiotherapeutic that contains 131I, a β-particle emitter, and MIP-1095, a urea-based ligand for prostate-specific membrane antigen. We report the first phase 1, dose-escalation study of 131I-MIP-1095 in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: This study enrolled men with mCRPC refractory to second-generation antiandrogen(s) and taxane chemotherapy. Dosimetry/biodistribution assessments were performed. Safety and tolerability were determined in subjects who qualified for therapeutic administration of 131I-MIP-1095 with maximum tolerated activity examined in a dose-ascending manner (3 + 3 design methodology). Disease outcomes including prostate-specific antigen (PSA) change, tumor response, survival, and circulating tumor cell concentration were assessed. RESULTS: A total of 9 subjects with mCRPC were included in this study. On the basis of dosimetry results, 5 of 9 patients were treated: 3 in cohort 1 (50 mCi) and 2 in cohort 2 (75 mCi). Accrual stopped at the cohort 2 activity level in response to the US Food and Drug Administration mandate for 131I-MIP-1095 manufacturing concerns. Parotid/salivary glands (3.5 Gy/Bq), liver (2.2 Gy/Bq), kidneys (1.3 Gy/Bq), and spleen (0.7 Gy/Bq) demonstrated the greatest extent of 131I-MIP-1095 exposure. There were no deaths, serious adverse events, or drug discontinuations due to treatment-emergent adverse events. Grade 1-2 thrombocytopenia, anemia, leukopenia, and dry mouth most commonly occurred. One subject (33.3%) exhibited maximum decline for the PSA response of 50% or greater. CONCLUSION: 131I-MIP-1095 demonstrated favorable dosimetry, biodistribution, and safety, as well as a modest PSA response supporting further investigation for treatment of men with mCRPC.Clinical Trial Registration: ClinicalTrials.gov identifier: NCT03030885, Registered January 25, 2017 (https://clinicaltrials.gov/ct2/show/NCT03030885).

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Laccetti AL, Bodei L, O'Donoghue JA, et al. A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Clin Nucl Med. 2023. PMID: 37812518. doi:10.1097/RLU.0000000000004818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。